HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

German Sleep Expert Urges Committee Not To Reverse-Switch Antihistamines

Executive Summary

Chair of the German Sleep Society, Ingo Fietze, calls on members of Germany's Expert Committee for Prescription to vote down the proposal to reverse-switch first-generation antihistamines with sedative effect for patients over the age of 65.

You may also be interested in...



Stada Says Lemocin’s OTC Status 'Vindicated' By German Switch Committee Decision

Stada's Lemocin cough lozenges survive a German reverse-switch threat, as does first generation anti-histamine dimenhydrinate, pointing to possible good news for the company's other major German OTC brand, Hoggar Night (doxylamine), which is also having its OTC status re-examined by the country's Expert Committee on Prescription.

Stada Blasts German Sleep Aid Reverse Switch

Stada criticizes German switch committee's recommendation to restrict access to first generation antihistamines with a sedative effect for over-65s. 

German Switch Committee Meets: Sumatriptan Goes Again, Antihistamine Reverse-Switch Rejected, For Now

Germany’s Expert Committee for Prescription recommends prescription-to-OTC reclassifications of sumatriptan for migraines and liquid ibuprofen, but rejects an OTC switch for ketoprofen and the reverse-switch of sedative antihistamines for over 65s.

Related Content

Topics

UsernamePublicRestriction

Register

RS148952

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel